Macrophage activation of lymphoma-bearing mice by liposome-mediated intraperitoneal IL-2 and IL-6 gene therapy

Chin Med J (Engl). 2000 Mar;113(3):281-5.

Abstract

Objective: To investigate the antitumor mechanism of interleukin-2 (IL-2) and interleukin-6 (IL-6) gene therapy.

Methods: Liposome encapsulated IL-2 DNA and IL-6 DNA were intraperitoneally (i.p.) injected into mouse lymphoma cell line (EL-4) lymphoma-bearing mice. Macrophage function (M phi) from the mice was assessed.

Results: Cytotoxicity, major histocompatibility (MHC) II expression and IL-1 and TNF secretion of the macrophages all augmented after i.p. injection of liposome encapsulated IL-2 DNA or IL-6 DNA. More efficient activation of macrophages was observed in mice treated with liposome encapsulated IL-2 DNA than IL-6 DNA. IL-2 gene therapy combined with IL-6 gene therapy showed the maximal activation of macrophages in the lymphoma-bearing mice.

Conclusion: IL-2 and IL-6 gene therapy can relieve the suppression of macrophages of the lymphoma-bearing mice, and efficiently activate the antitumor immune responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Genetic Therapy*
  • Injections, Intraperitoneal
  • Interleukin-2 / genetics*
  • Interleukin-2 / metabolism
  • Interleukin-6 / genetics*
  • Interleukin-6 / metabolism
  • Liposomes
  • Lymphoma / immunology
  • Lymphoma / therapy*
  • Macrophage Activation*
  • Macrophages, Peritoneal / immunology
  • Mice
  • Tumor Cells, Cultured

Substances

  • Interleukin-2
  • Interleukin-6
  • Liposomes